Ligand-independent androgen receptor activity

Scott M. Dehm, Donald J. Tindall

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The androgen receptor (AR) is important for the growth and survival of normal and malignant prostate cells. As such, androgen-deprivation therapy is the current mainstay of systemic prostate cancer therapy. Invariably, prostate cancer will develop resistance to androgen deprivation and recur with a castration-recurrent phenotype. The surprising finding that castration-recurrent prostate cancer is still reliant on AR activity indicates that novel means of targeting the AR could be developed to treat this stage of the disease. Several mechanisms, including ligand-independent activation, have been described as means by which the AR can achieve a critical level of activity in castration-recurrent prostate cancer. This chapter will explore the mechanisms of ligand-independent AR activation and highlight some recent findings generated in the Tindall laboratory.

Original languageEnglish (US)
Title of host publicationAndrogen Action in Prostate Cancer
PublisherSpringer US
Pages427-449
Number of pages23
ISBN (Print)9780387691770
DOIs
StatePublished - 2009

Fingerprint

Androgen Receptors
Ligands
Castration
Prostatic Neoplasms
Androgens
Chemical activation
Prostate
Phenotype
Therapeutics
Growth

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Dehm, S. M., & Tindall, D. J. (2009). Ligand-independent androgen receptor activity. In Androgen Action in Prostate Cancer (pp. 427-449). Springer US. https://doi.org/10.1007/978-0-387-69179-4_19

Ligand-independent androgen receptor activity. / Dehm, Scott M.; Tindall, Donald J.

Androgen Action in Prostate Cancer. Springer US, 2009. p. 427-449.

Research output: Chapter in Book/Report/Conference proceedingChapter

Dehm, SM & Tindall, DJ 2009, Ligand-independent androgen receptor activity. in Androgen Action in Prostate Cancer. Springer US, pp. 427-449. https://doi.org/10.1007/978-0-387-69179-4_19
Dehm SM, Tindall DJ. Ligand-independent androgen receptor activity. In Androgen Action in Prostate Cancer. Springer US. 2009. p. 427-449 https://doi.org/10.1007/978-0-387-69179-4_19
Dehm, Scott M. ; Tindall, Donald J. / Ligand-independent androgen receptor activity. Androgen Action in Prostate Cancer. Springer US, 2009. pp. 427-449
@inbook{54e3d7ce3d2d4756970c37a029d7f975,
title = "Ligand-independent androgen receptor activity",
abstract = "The androgen receptor (AR) is important for the growth and survival of normal and malignant prostate cells. As such, androgen-deprivation therapy is the current mainstay of systemic prostate cancer therapy. Invariably, prostate cancer will develop resistance to androgen deprivation and recur with a castration-recurrent phenotype. The surprising finding that castration-recurrent prostate cancer is still reliant on AR activity indicates that novel means of targeting the AR could be developed to treat this stage of the disease. Several mechanisms, including ligand-independent activation, have been described as means by which the AR can achieve a critical level of activity in castration-recurrent prostate cancer. This chapter will explore the mechanisms of ligand-independent AR activation and highlight some recent findings generated in the Tindall laboratory.",
author = "Dehm, {Scott M.} and Tindall, {Donald J.}",
year = "2009",
doi = "10.1007/978-0-387-69179-4_19",
language = "English (US)",
isbn = "9780387691770",
pages = "427--449",
booktitle = "Androgen Action in Prostate Cancer",
publisher = "Springer US",

}

TY - CHAP

T1 - Ligand-independent androgen receptor activity

AU - Dehm, Scott M.

AU - Tindall, Donald J.

PY - 2009

Y1 - 2009

N2 - The androgen receptor (AR) is important for the growth and survival of normal and malignant prostate cells. As such, androgen-deprivation therapy is the current mainstay of systemic prostate cancer therapy. Invariably, prostate cancer will develop resistance to androgen deprivation and recur with a castration-recurrent phenotype. The surprising finding that castration-recurrent prostate cancer is still reliant on AR activity indicates that novel means of targeting the AR could be developed to treat this stage of the disease. Several mechanisms, including ligand-independent activation, have been described as means by which the AR can achieve a critical level of activity in castration-recurrent prostate cancer. This chapter will explore the mechanisms of ligand-independent AR activation and highlight some recent findings generated in the Tindall laboratory.

AB - The androgen receptor (AR) is important for the growth and survival of normal and malignant prostate cells. As such, androgen-deprivation therapy is the current mainstay of systemic prostate cancer therapy. Invariably, prostate cancer will develop resistance to androgen deprivation and recur with a castration-recurrent phenotype. The surprising finding that castration-recurrent prostate cancer is still reliant on AR activity indicates that novel means of targeting the AR could be developed to treat this stage of the disease. Several mechanisms, including ligand-independent activation, have been described as means by which the AR can achieve a critical level of activity in castration-recurrent prostate cancer. This chapter will explore the mechanisms of ligand-independent AR activation and highlight some recent findings generated in the Tindall laboratory.

UR - http://www.scopus.com/inward/record.url?scp=84901102369&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901102369&partnerID=8YFLogxK

U2 - 10.1007/978-0-387-69179-4_19

DO - 10.1007/978-0-387-69179-4_19

M3 - Chapter

AN - SCOPUS:84901102369

SN - 9780387691770

SP - 427

EP - 449

BT - Androgen Action in Prostate Cancer

PB - Springer US

ER -